Company Profile

Established in Shenzhen, China in 1999, LifeTech Scientific Corporation (Stock Code: 1302.HK) specializes in the R&D, manufacturing, and sales of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases.

The Company offers innovative solutions for structural heart diseases, peripheral vascular diseases, bradycardia and neurovascular conditions. The Company also possesses the world's first innovative iron-based bioabsorbable material technology platform.

Guided by the core strategy of“innovation”and“internationalization”, the Company maintains a leading market position for its key products in the home country and has established 7 subsidiaries overseas, extending its sales network to nearly 120 countries and regions worldwide.

Mission

Improving lives with innovative interventional medical technology
Vision

Becoming a globally-recognized, trustworthy and innovative interventional medical device enterprise
Core Value

Accountability, Innovation, Cooperation, Gratitude

About Us

Our Business

Structural Heart Business

We provide structural heart disease patients with diversified minimally invasive interventional medical device solutions around the world. We have developed four generations of congenital heart disease occluders to catering different clinical needs, and we also developed technology-advanced left atrial appendage (LAA) closure systems, of which the LAmbre? Plus LAA Closure System has been approved by the FDA to initiate an investigator-initiated pre-market clinical trial, and the trial has obtained medical insurance coverage in the United States. In addition, we are now actively developing interventional solutions for valvular diseases.

View Disease Solutions ＋

Peripheral Vascular Business

We provide peripheral vascular disease patients with safe and effective endovascular solutions, striving to bring a comprehesive device treatment for patients around the world, including the treatment of aortic?diseases, venous?diseases, and arterial?and?venous?embolizations.

View Disease Solutions ＋

Cardiac Electrophysiology Business

We leverage world-leading technology to bring domestically-made complete solutions to bradycardia patients in China with world-class quality and advanced technology. In addition, in partnership with Affector Medtech, we are developing a comprehensive portfolio that spans 3D electro-anatomical mapping and multi-energy ablation, delivering precise, safe, and innovative end-to-end solutions for patients with arrhythmias.

Iron-based Bioabsorbable Material

We develop the world’s unique iron-based bioabsorbable material technology through our subsidiary Biotyx Medical (Shenzhen) Co., Ltd. After nearly two decades of dedication to R&D, the first three core products for the treatment of coronary heart disease, pulmonary vascular stenosis and infrapopliteal artery stenosis, are currently at different phases of clinical trial. The usage of this novel iron-based bioabsorbable material will help to develop unprecedented, safe, and effective treatment options for patients around the world.

View Disease Solutions ＋

Innovation for World Patients

We are continuously providing safe and effective innovative interventional medical device solutions for doctors and patients around the world, exerting every effort to promote our novel devices and advanced technology across the globe.

Headquarters
Subsidiaries

120~

Countries and Regions Coverage
1,000+

Distributors in World Market
2,631

Global Patents
(Include Application)

OG视讯官网

About Us